Cobicistat, a pharmacoenhancer for HIV treatments

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition. In addition, its water solubility may lend itself to coformulation with other drugs. Renal adverse effects and a considerable drug interaction potential limit its clinical utility and caution is required when using it. A fixed-dose combination product containing cobicistat in addition to elvitegravir, tenofovir and emtricitabine, and providing a one-pill, once-a-day antiretroviral regimen was recently approved.

Original languageEnglish (US)
Pages (from-to)233-237
Number of pages5
JournalDrugs of Today
Issue number4
StatePublished - Apr 1 2013


  • Cobicistat
  • Cytochrome P450 3A4 inhibitors
  • GS-9350
  • Pharmacoenhancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Cobicistat, a pharmacoenhancer for HIV treatments'. Together they form a unique fingerprint.

Cite this